Trials / Completed
CompletedNCT01174004
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pimavanserin tartrate | pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks |
| DRUG | placebo | placebo, tablet, once daily by mouth for 6 weeks |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2010-08-03
- Last updated
- 2014-03-26
- Results posted
- 2014-03-26
Locations
63 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01174004. Inclusion in this directory is not an endorsement.